Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Electra Therapeutics Inc. (ETRA : NSDQ)

• Company Description    Electra Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's lead product candidate includes ipsoprubart. Electra Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 46

• Price / Volume Information    Yesterday's Closing Price: $9.05 Daily Weekly Monthly 20 Day Moving Average: 540,578 shares Shares Outstanding: 62.77 (millions) Market Capitalization: $568.04 (millions) Beta: 52 Week High: $15.50 52 Week Low: $8.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.57% -29.04% 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 230 EAST GRAND AVENUE SUITE S-100 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 888-743-2290 fax: - ir@electra-therapeutics.com http://www.electra-therapeutics.com

• General Corporate Information    Officers Quehuong (Kathy) Dong - Chief Executive Officer and President Nancy Stagliano - Chairperson Chris Clark - Chief Financial Officer Matthew Fust - Director Thomas Geninatti - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 284825106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 62.77 Most Recent Split Date: (:1) Beta: Market Capitalization: $568.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - - 03/31/26 - - Current Ratio 09/30/26 - - 06/30/26 - - 03/31/26 - - Quick Ratio 09/30/26 - - 06/30/26 - - 03/31/26 - - Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - - 03/31/26 - - Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©